On March 6, 2026, Mineralys Therapeutics, Inc. received notice from the FDA that its New Drug Application for lorundrostat, aimed at treating hypertension, was accepted, with a target action date set for December 22, 2026. The Phase 2 trial showed a significant average blood pressure reduction of 11.1 mmHg, indicating promising results.